title: Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
abstract: The mammalian target of rapamycin (mTOR) inhibitor, in combination with other chemotherapeutic drugs, has been used for treatment of breast cancer that develops resistance to endocrine therapy. However, the efficacy and safety need further evaluation. Here, we report a meta-analysis of randomized controlled trials (RCT) in breast cancer patients undergoing chemotherapy using steroid (exemestane) or nonsteroid (letrozole) aromatase inhibitors with or without mTOR inhibitors (everolimus). The overall response rate (ORR), progression-free survival (PFS), clinical benefi;t rate with 95% confidence interval (CI), and the major toxicities/adverse effects were analyzed. Data were extracted from twelve studies that meet the selection criteria. Among these, six studies that enrolled 3693 women received treatment of everolimus plus exemestane, or placebo with exemestane. The results showed that everolimus plus exemestane significantly increased the ORR relative risk (relative risk = 9.18, 95% CI = 5.21-16.15), PFS hazard ratio (hazard ratio = 0.44, 95% CI = 0.41-0.48), and clinical benefi;t rate (relative risk = 1.92, 95% CI 1.69-2.17) compared to placebo control, while the risks of stomatitis, rash, hyperglycemia, diarrhea, fatigue, anorexia and pneumonitis also increased. Three studies that enrolled 715 women who received everolimus as neoadjuvant therapy were analyzed. Compared to chemotherapy with placebo, chemotherapy plus everolimus did not increase the ORR relative risk (relative risk = 0.90, 95% CI = 0.77-1.05). Meanwhile, two other studies that enrolled 2104 women examined the efficacy of temsirolimus (or placebo control) plus letrozole. The results indicated that emsirolimus plus letrozole did not increase the ORR relative risk and clinical benefi;t rate (p > 0.05). Together, these data suggest that the combined mTOR inhibitor (everolimus) plus endocrine therapy (exemestane) is superior to endocrine therapy alone. As a neoadjuvant, everolimus did not increase the ORR, while temsirolimus plus letrozole treatment has limited effect on the ORR and the CBR of breast cancer patients.
authors.affiliation: Department of Hematology and Hematological Laboratory Science, School of Medical Science and Laboratory Medicine, Jiangsu University Zhenjiang 212013, China.
authors.forename: Longwei
authors.initials: L
authors.lastname: Qiao
authors.affiliation: Department of Hematology and Hematological Laboratory Science, School of Medical Science and Laboratory Medicine, Jiangsu University Zhenjiang 212013, China.
authors.forename: Yuting
authors.initials: Y
authors.lastname: Liang
authors.affiliation: Department of Anatomy and Cell Biology, Rush University Medical Center Chicago, IL 60612, USA.
authors.forename: Ranim R
authors.initials: RR
authors.lastname: Mira
authors.affiliation: Department of Hematology and Hematological Laboratory Science, School of Medical Science and Laboratory Medicine, Jiangsu University Zhenjiang 212013, China ; Department of Anatomy and Cell Biology, Rush University Medical Center Chicago, IL 60612, USA.
authors.forename: Yaojuan
authors.initials: Y
authors.lastname: Lu
authors.affiliation: Department of Hematology and Hematological Laboratory Science, School of Medical Science and Laboratory Medicine, Jiangsu University Zhenjiang 212013, China.
authors.forename: Junxia
authors.initials: J
authors.lastname: Gu
authors.affiliation: Department of Hematology and Hematological Laboratory Science, School of Medical Science and Laboratory Medicine, Jiangsu University Zhenjiang 212013, China ; Department of Anatomy and Cell Biology, Rush University Medical Center Chicago, IL 60612, USA.
authors.forename: Qiping
authors.initials: Q
authors.lastname: Zheng
keywords: aromatase inhibitors; breast cancer; chemotherapy; mTOR inhibitors; meta-analysis